On Friday, Sanofi SA SNY said it is negotiating with Clayton Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business. According to the Bloomberg report, the deal could be valued at about 15 billion euros ($16.4 billion), making it one of the largest European transactions this year. Sanofi is likely to retain a minority stake in the Opella business. In October 2023, Sanofi announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development pipeline and cut costs. Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines. As per a Bloomberg report, two private equity firms, Clayton Dubilier & Rice and PAI Partners, made separate bids for Sanofi's consumer health division.